Surrozen Announces Changes to its Board of Directors

• Surrozen appointed Mace Rothenberg, M.D. to its Board of Directors. As Chief Medical Officer of Pfizer, Mace led Pfizer’s Worldwide Medical & Safety organization. He also served as a member of Pfizer’s Portfolio Strategy and Investment Committee, Worldwide Research, Development, and Medical Leadership Team, and Blueprint Leaders Forum.

• Christopher Chai has also been appointed to the Board of Directors. As a Venture Partner at SR One Capital Management, Christopher brings over 20 years of experience. Before joining SR One, he served as Chief Financial Officer of Principia Biopharma, where he led the company from an early-stage private venture-backed company to its acquisition by Sanofi for $3.7 billion. He was previously CFO at MAP Pharmaceuticals and Vice President, Treasury, and Investor Relations at CV Therapeutics.

Surrozen is a privately held biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.